apitegromab tirzepatide Apitegromab, a selective antimyostatin monoclonal antibody targeting muscle preservation, added to reduced muscle loss by ~55% over 24 weeks without affecting overall weight loss in the phase 2 EMBRAZE trial. https://t.co/jDqTipQrZa Weight loss and better health

Check your formulary, understand the requirements, and work closely with your prescribing provider to submit a strong prior authorization request

Book a free discovery call with me here.

doi: 10.1016/j.genhosppsych.2022.07.006

We solicited comments on whether there are other methods of allocating discounts in these circumstances that would more accurately represent ASP

However, these cuts are expected to affect the bottom line of pharmacy benefit managers (PBM) as they receive significant rebates from drug makers, more so than the companies themselves.

LW: Conceptualization, Writing review & editing, Supervision, Funding acquisition